Coronavirus

Study includes healthy individuals and those who had progressive multiple sclerosis with the nasally administered treatment.

The fourth dose of the bivalent vaccine elicited improved Omicron BA.4/BA.5-neutralizing antibody responses compared to participants who received 3 doses of the original vaccine.

Nightlife transmission of COVID-19 affected a larger number of younger individuals but caused fewer household outbreaks in 2020.

The efficacy of 2 doses against Omicron infection was highest when the second vaccine dose was given in the third trimester of pregnancy compared with the first or second trimesters.

Due to the success of mRNA technology with COVID-19, there has been a significant increase in research looking into utilizing mRNA technology, and more specifically, how it can help to advance vaccine development.

The effectiveness of 2 doses against Omicron infection was highest when the second dose was given in the third trimester of pregnancy compared with the first or second trimesters.

Companies seek FDA approval for individuals aged 12 years and older to receive vaccinations for their primary series.

Patients who had relapsed or treatment-resistant cancer at baseline, or those who had more severe acute COVID-19 infections, were less likely to develop long COVID-19.

The COVID-19 and flu test is a single-use at-home test kit that uses self-collected nasal swab samples and provides results in approximately 30 minutes.

Results of the ACTIV-6 study showed that high dose ivermectin use did not demonstrate a clinical benefit for mild to moderate COVID-19.

In a subgroup analysis, patients with COVID-19 who received conventional oxygen support also benefitted, having 20 fewer deaths per 1000 patients when given remdesivir.

One of the major concerns about getting a flu vaccine is its safety for women during pregnancy.

Approximately 48.1% of those who received vaccines had family members or friends who were either sick or recovered from the illness compared with 26.9% who were unvaccinated.

The findings are the first to explain the mechanisms of any Kawasaki disease, a rare childhood inflammatory condition that is triggered by different viruses.

Antibodies from an original COVID-19 vaccination may treat the mRNA booster vaccine as a virus that needs to be cleared.

The risk of new-onset cardiometabolic diseases was significantly elevated post-COVID-19 infection compared to pre-COVID-19 infection.

Findings indicate that primary vaccines can be improved among younger, rural-dwelling individuals.

Arrhythmia was found to be the most common cardiovascular complication of COVID-19.

Link between male or female sex and the severity of COVID-19 may be found in a subset of regulatory T cells.

US adults have a slightly stronger preference for fewer adverse events in relation to pediatric COVID-19 vaccination, study results show.

Relative efficacy of nirmatrelvir–ritonavir appears similar across risk groups, but older adults at risk of severe COVID-19 may benefit more.

A booster vaccine for COVID-19 increased the concentration of antibodies in older patients more than younger patients.

Long COVID can impact quality of life, with some symptoms lasting for 1 year before the patient recovers to baseline.

Cancer screening rates were still below the expected rates of return in both 2021 and 2022.

Single nasal swab test can determine whether a patient has COVID-19, influenza, respiratory syncytial virus, or a combination of these viruses in as little as 2 hours.

IQVIA report states that appropriate reimbursement for all health care professionals who provide immunization services would encourage their ongoing provision of vaccines.

Rapid antigen tests, which can identify infected individuals before they present symptoms, are considered a promising means of reducing the spread of COVID-19.

COVID-19 vaccines are known to have one of the most complex schedules that the average pharmacist has ever had to manage for a vaccine directed towards a single preventable disease.

The efficacy and adverse effects associated with COVID-19 vaccines is a leading cause of hesitancy in parents, according to a new study.

The test, called VirSNiP SARS-CoV-2 Spike F486P, is for research use only and specifically targets the unique mutation F486P found within the XBB.1.5 Omicron sub-variant.